Lv6
2150 积分 2024-08-13 加入
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
3天前
已完结
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
6天前
已完结
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
6天前
已完结
Innovation in Event Adjudication—Human vs Machine
7天前
已完结
Independence of clinical events committees: A consensus statement from clinical research organizations
7天前
已完结
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
8天前
已完结
Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors
8天前
已关闭
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
8天前
已完结
Long-Acting Factor XI Inhibition and Periprocedural Bleeding
9天前
已完结
Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective
9天前
已完结
皖公网安备34019202002308
